Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.175p +1.70% 10.475p 187,248 16:35:17
Bid Price Offer Price High Price Low Price Open Price
10.30p 10.65p 10.60p 10.15p 10.45p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.15 -7.00 -4.75 14.6

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Share Charts

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Intraday Immupharma Chart

Intraday Immupharma Chart

Immupharma (IMM) Discussions and Chat

Immupharma Forums and Chat

Date Time Title Posts
09/11/201814:57IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES33,685
07/11/201810:42Sell order10
16/8/201810:44ImmuPharma interview2
30/4/201808:55ImmuPharma - Global Potential Blockbusters & Huge Potential Upside103
24/4/201808:47ImmuPharma Q&A-

Add a New Thread

Immupharma (IMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:51:1810.0010.10O
16:02:1910.602,400254.40AT
15:57:3710.284,000411.00O
15:47:2110.609,4821,005.09AT
15:47:1410.589,409995.00O
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
12/11/2018
08:20
Immupharma Daily Update: Immupharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 10.30p.
Immupharma has a 4 week average price of 9.06p and a 12 week average price of 9.06p.
The 1 year high share price is 193p while the 1 year low share price is currently 9.06p.
There are currently 139,467,430 shares in issue and the average daily traded volume is 506,677 shares. The market capitalisation of Immupharma is £14,609,213.29.
11/9/2018
17:44
obiterdicta: OT You haven't answered the points made. If you have any points to make I will consider them. You make generic points about valuation which are understood. See my response to UKDB below. UKDannyboy Thanks for the re-cap. I am not trying to convince anyone. If you look back at the thread it was Merlion who first raised cash assets to support his valuation. I did not raise it first but responded to Merlion's point. My point is in order to crystalise share price appreciation you need some inflection points, for example trial results. I can see no inflection points on the horizon for IMM but accept your point that Lupuzor may realise some value on conclusion of the MAP. The MAP does not conclude for another 2 years. My view is that Lupuzor realizing any value is a remote possibility and is some way off. So what inflection points do you see coming up for IMM to crsytalise share price appreciation? Do you accept my point that momentum is against IMM and management have lost credibility? OD
10/9/2018
10:46
cockerspaniel: Sicilian: Yes,the die was cast long before Tim became involved. There remain some serious questions to be asked about the design of the phase III and the SPA, which was done by Cephalon (Immupharma only found out about it afterwards). Cephalon appear, with hindsigt, to have put as little resources into the development of Lupuzor as possible, and agreed the absolute bare minimum trial - i.e. one which would work only if Lupuzor performed exceptionlly well. Immupharma's management, however, seem to have represented things differently. That is hardly unusual in biotech, as founders and management are notoriously over-optimistic. So, what has Tim done:essentially he got the share price up, raised money from some private investors at a high price - the previous placings being done at a much lower level and were taken by serious investors (not mentioning any names). The unfortunate private investors may view the situation differently. Nothing that Tim or Dimitri do happens without the agreement of Robert Zimmer, who has been the driving force behind the company well before it came to the London market (sorry Richard and Dimitri), Now, what about Nobby? He has his own agenda - management change at Immupharma and a role for himself. That's not going to happen by silly postings on bulletin boards, but Nobby is nothing if not persistent. What about Immupharma? Hard to say, but looking at it from the perspective of a disappointed shareholder is not going to help. There might be some value for vultures or the cash might end up paying management's not ungenerous salaries for a while longer. Anyway, a lot has happened in 12 years and most of us (RIP Richard Warr) have lived to tell the tale.
16/6/2018
20:46
spawny100: Never mind last couple of years petroc - IMM share price is back to 2003 levels. Anyone who sees value at these prices needs to seriously analyse why imo.
01/5/2018
13:04
the_merlion: Mind you Ham, you have done better trolling then Growth and Nobby today. Fair play to you, I am sure you will make those thousands of pounds you lost with a entry at 150 back in the day. I guess you are a little scared to punt in, as you now only have 25% or the original pot left to work, but that is your own stupid fault LMFAO. hamhamham1 - 01 May 2018 - 13:49:36 - 30009 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM Personally i trust Panmures ability to calculate an asset price over the posters on here. hamhamham1 - 01 May 2018 - 13:21:59 - 30000 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM IMHO. If the company's share price was sub 40p before all the hype of the p3 started (end 2016) with still then with all that hope ahead. Then after the bad p3 readout then I reckon half that is a more than generous share price. hamhamham1 - 01 May 2018 - 12:20:34 - 29991 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM My money is still on it hitting the Panmure Gordon target of 22p. Time will tell. hamhamham1 - 01 May 2018 - 12:03:20 - 29987 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM If I bought shares here now, I would be buying on the hope that something comes over the horizon which is not currently scheduled to happen. Is that investing or gambling? hamhamham1 - 01 May 2018 - 11:28:27 - 29980 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM What's the odds for hit 28p then drop?
27/4/2018
07:26
growthinvestor2001: spmc - I remember you making wild claims about IMM share price too - look how that worked out. Just keep it to yourself....try and stop ramping / pumping for just one minute yeah?
24/4/2018
09:30
hamhamham1: Merlion. Look, research companies are money pits they dilute shares and raise money all day long. They suck up money and nearly always end up with nothing of value to show for it. IMM share price went up based upon an immenant good p3 readout and thus real saleable asset value. It failed by over x5 the target level p value. The 22p is based upon that and not some pi investor hopes.
19/4/2018
10:13
hamhamham1: Shares Logo Menu Shares News ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price. Deal now » Find out how to deal online from £1.50 Issue Date: 17 Apr 2018 Save Share Sign In or Subscribe to a Premium account to comment. Lisa-Marie Janes profile pic Lisa-Marie Janes Related news Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry Market report: Cheers for Weir, downgrades for Debenhams Shares in cyber security and ID firm GB jump 12%, here’s why Hammerson listens to the market and walks away from Intu deal Rio Tinto defies major disruptions and avoids large downgrade to production guidance Shares in Animalcare slump on profit warning Dignity resurrected as deaths soar and more people opt for premium funerals than expected Asset manager Jupiter hit by clients withdrawing money and negative market conditions Market report: Hammerson up as M&A deal shelved Why asset manager Ashmore is in vogue today Shares Magazine Latest Issue Cover Latest Issue: 19 Apr 2018 Subscribe now @SharesMag @SharesMagDan: Today, 11:03 @wheeliedealer Hi WD - can you think of any stocks with a large net cash position relative to market cap? Thanks @SharesMagSteve: Today, 10:34 RT @SHARESmag: Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry $WEIR hxxps://t.co/JMdr230; @SharesMagDan: Today, 10:17 RT @SHARESmag: Quality management is part of the success or failure of a company, which is why change at the top can often act as a catalys… < Previous Next > Terms And Conditions Investment Warning Privacy Disclaimers About Shares The Shares Team Contact Us
18/4/2018
10:46
hamhamham1: ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price.
12/4/2018
15:30
top tips: -- Sales $6.25 billion pa (above), 30% royalty to Immupharma + $200 million pa licensing fee to Immupharma; gives $1.875 billion + $200 m = $2.075 billion pa revenues to Immupharma. 96%+ gross margin, say $1.57 billion pa net (after gross margin & tax, etc), on PE ratio of 20 = $31.4 billion market capitalisation for Immupharma = Approx Immupharma share price £179. - 500,000 Lupuzor lupus patients (double above) at $25k pa = $12.5 billion pa revenue i.e. 10% of Global lupus sufferers, or 33.33% of developed markets sufferers. = Approx Immupharma share price £358. And then add something for the numerous other indications Lupuzor P140 could treat, including rheumatoid arthritis with a market size of $28 billion pa.
12/4/2018
10:29
hottingup: - 250,000 Lupuzor lupus patients at $25k pa = $6.25 billion pa revenue i.e. 5% of Global lupus sufferers, or 16.66% of developed markets sufferers. -- Sales $6.25 billion pa (above), 30% royalty to Immupharma + $200 million pa licensing fee to Immupharma; gives $1.875 billion + $200 m = $2.075 billion pa revenues to Immupharma. 96%+ gross margin, say $1.57 billion pa net (after gross margin & tax, etc), on PE ratio of 20 = $31.4 billion market capitalisation for Immupharma = Approx Immupharma share price £179. - 500,000 Lupuzor lupus patients (double above) at $25k pa = $12.5 billion pa revenue i.e. 10% of Global lupus sufferers, or 33.33% of developed markets sufferers. = Approx Immupharma share price £358. And then add something for the numerous other indications Lupuzor P140 could treat, including rheumatoid arthritis with a market size of $28 billion pa.
Immupharma share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181112 19:40:32